HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells

SIMPLE SUMMARY: Pancreatic cancer is currently difficult to treat, but the drug cisplatin represents one of the most important therapeutic options. We find that cells derived from this cancer fall into two classes regarding their sensitivity towards cisplatin, and we observe that cells with high exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ewers, Katharina M., Patil, Shilpa, Kopp, Waltraut, Thomale, Jürgen, Quilitz, Tabea, Magerhans, Anna, Wang, Xin, Hessmann, Elisabeth, Dobbelstein, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699576/
https://www.ncbi.nlm.nih.gov/pubmed/34944784
http://dx.doi.org/10.3390/cancers13246163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699576/
https://www.ncbi.nlm.nih.gov/pubmed/34944784
http://dx.doi.org/10.3390/cancers13246163

Ejemplares similares